Hundreds of prescription drugs sold in the United States are set to become more expensive in 2026, even as the Trump administration pushes pharmaceutical companies to rein in costs, according to new data from healthcare research firm 3 Axis Advisors.
The analysis shows that manufacturers intend to raise list prices on at least 350 branded medications, including vaccines for COVID, RSV, and shingles, as well as high-profile treatments such as the cancer drug Ibrance.
The scale of the planned increases exceeds last year’s pace. At the same stage in 2024, companies had announced price hikes for just over 250 drugs. For the coming year, the median increase is roughly 4%, about the same as in 2025.
The figures reflect list prices only and do not take into account rebates paid to pharmacy benefit managers or other discounts negotiated across the drug supply chain.
While most changes point upward, manufacturers are also planning list price reductions for about nine medicines. Among them is a cut of more than 40% for the diabetes drug Jardiance and three related treatments sold by Boehringer Ingelheim and Eli Lilly.
Neither Boehringer Ingelheim nor Eli Lilly immediately responded to questions about the reason for the Jardiance price cuts.
Jardiance is one of 10 drugs whose prices were negotiated downward by the U.S. government for the Medicare program serving people 65 and older in 2026. As part of that process, Boehringer and Lilly reduced the drug’s price by about two-thirds.
Despite such negotiations, Americans continue to pay far more for prescription medicines than patients in other wealthy countries — often close to triple the cost — an issue President Donald Trump has repeatedly highlighted while urging drugmakers to align U.S. prices with those abroad.
The announced hikes are coming even as Trump has reached agreements with 14 pharmaceutical companies to lower prices on certain medicines for Medicaid recipients and for people paying cash. Companies involved in those deals include Pfizer, Sanofi, Boehringer Ingelheim, Novartis, and GSK — all of which are also planning price increases on some drugs starting Jan. 1.
“These deals are being announced as transformative when, in fact, they really just nibble around the margins in terms of what is really driving high prices for prescription drugs in the U.S.,” said Dr. Benjamin Rome, a health policy researcher at Brigham and Women’s Hospital in Boston.
Rome said drugmakers appear to be pushing list prices as high as possible while privately negotiating discounts with insurers and pharmacy benefit managers, then establishing separate prices for patients who pay cash.
A spokesman for the Department of Health and Human Services declined to comment.
Pfizer accounted for the largest number of planned list price increases, with hikes affecting around 80 different drugs. Those include the cancer treatment Ibrance, the migraine drug Nurtec, and the COVID therapy Paxlovid, along with hospital-administered medications such as morphine and hydromorphone.
Most of Pfizer’s increases fall below 10%, though the company plans a 15% increase for its COVID vaccine Comirnaty. Some lower-cost hospital drugs are slated for much steeper jumps, in a few cases rising more than fourfold.
Pfizer said it has kept the average list price increase for its innovative medicines and vaccines in 2026 below the overall inflation rate.
“The modest increase is necessary to support investments that allow us to continue to discover and deliver new medicines as well as address increased costs throughout our business,” the company said.
Large, double-digit U.S. drug price hikes were once far more routine, but manufacturers have pulled back amid growing criticism from lawmakers and new policies that penalize companies if Medicare prices rise faster than inflation.
GSK said it plans to raise prices on about 20 drugs and vaccines, with increases ranging from 2% to 8.9%. The company said it remains committed to reasonable pricing and that the adjustments are needed to support scientific innovation.
Additional price changes — both increases and cuts — are expected to be announced in early January, traditionally the busiest period for annual drug price adjustments.
3 Axis Advisors is a consulting firm that works with pharmacist organizations, health plans, and pharmaceutical industry-related groups on pricing and supply chain issues. It is affiliated with, and shares staff with, the drug pricing nonprofit 46brooklyn.
{Matzav.com}